This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Fondazione Irccs Istituto Nazionale Dei Tumori. Active years: 2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020
Title: Innovator Spotlight: Alessandro Massimo Gianni
Introduction: Alessandro Massimo Gianni is a notable inventor based in Castelveccana, Italy. His work focuses on innovations within the field of cancer immunotherapy, specifically through the development of novel drug modalities. With one patented invention, Gianni is contributing to advancements in medical science that aim to improve treatment options for patients facing cancer.
Latest Patents: Gianni holds a patent titled "Bispecific antibody binding TRAIL-R2 and CD3." This groundbreaking invention pertains to cancer immunotherapy and introduces bispecific antibodies designed to bind both the TRAIL tumor-associated antigen and the T lymphocyte CD3. His invention addresses the challenges of drug resistance while minimizing toxicity, offering a promising approach in the treatment of tumors. Additionally, the patent includes compositions comprising these bispecific antibodies along with a labeling agent, as well as pharmaceutical compositions utilizing these innovative antibodies.
Career Highlights: Gianni is associated with the Fondazione IRCCS Istituto Nazionale dei Tumori, a prestigious institution committed to cancer research and treatment. His work at this leading research center further enhances his contributions to oncology and underscores his commitment to developing effective cancer therapies that could substantially improve patient outcomes.
Collaborations: Throughout his career, Gianni has collaborated with esteemed colleagues such as Mariangela Figini and Alessandro Satta, who also share a dedication to advancing the field of cancer treatment. Together, they work on pioneering projects aimed at enhancing therapeutic efficacy and patient safety in oncology.
Conclusion: Alessandro Massimo Gianni exemplifies the spirit of innovation in the field of medicine. His patent for bispecific antibodies signifies a substantial step forward in immunotherapy for cancer, reflecting his commitment to addressing the pressing challenges in oncology. As research continues and collaborations foster new ideas, Gianni remains a pivotal figure in the pursuit of effective cancer treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile